Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Strategy of Intracoronary Imaging Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels (STENTLESS II)

10 de noviembre de 2026 actualizado por: Erli Zhang, China National Center for Cardiovascular Diseases

Strategies of Intracoronary Imaging Guided Drug-coated Balloons (DCB) Versus Angiography Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels Trial (STENTLESS II)

A number of 2570 patients scheduled for percutaneous coronary intervention (PCI) with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm) suitable for DCB implantation are openly randomized 1:1 to either intracoronary imaging guidance or angiographic guidance groups. The primary objective is to determine whether the IVUS/OCT-guided DCB strategy reduces the incidence of target vessel failure (TVF) at 12 months compared with the coronary angiography (CAG)-guided strategy.

Descripción general del estudio

Descripción detallada

This study is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of IVUS/OCT-guided drug-coated balloon (DCB) strategy compared with a CAG-guided strategy in patients with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm). Both groups will follow standardized angiographic safety criteria, with bailout drug-eluting stent (DES) implantation permitted when necessary. In the IVUS/OCT-guided group, lesion assessment, preparation, DCB treatment, and bailout stenting decisions will be optimized according to a predefined IVUS/OCT criterion, whereas the CAG-guided group will undergo treatment primarily based on angiographic assessment.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

2570

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Beijing, Porcelana, 100037
        • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Participants must meet all of the following three criteria:

  1. Age ≥18 years;
  2. De novo lesions of large coronary vessels with the diameter of target lesion reference vessel ≥ 2.75 mm;
  3. One or more trial target vessel (LAD, LCX or RCA) is considered to require intervention and is suitable for treatment with DCB.

Exclusion Criteria:

Participants who meet any of the following conditions are not eligible for inclusion:

  1. Patients with hemodynamically unstable acute coronary syndrome
  2. Previous percutaneous coronary intervention (including stent implantation, plain old balloon angioplasty, and DCB angioplasty) on the target vessel within 12 months
  3. In-stent restenosis requiring revascularization
  4. Complex Coronary Bifurcation Lesions*
  5. Lesions with any of the following anatomical characteristics are presumably not suitable for DCB treatment:

1) Chronic total occlusion* 2) Left main coronary artery lesion and left main bifurcation lesion 3) Venous or arterial graft lesion 4) Moderated-Severe tortuous, or severe angulated vessels 6. cardiogenic shock 7. Concurrent medical condition with a life expectancy of less than 1 year. 8. Known contraindication to medications such as Aspirin, Heparin, antiplatelet drugs, or contrast

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intracoronary imaging-Guided Drug-coated balloon strategy

DCB diameter and length will be determined based on Intracoronary imaging measurements, with additional lesion preparation performed at the operator's discretion according to the predefined intravascular imaging optimization criteria.

In the intracoronary imaging-guided group, lesion preparation will be guided by intravascular imaging findings, with additional balloon dilatation or specialized devices used as needed. Following lesion preparation and DCB treatment, repeat Intracoronary imaging will be performed to assess lumen gain, residual stenosis, dissection morphology, and elastic recoil. The acceptable minimum lumen area (MLA) is ≥ 4.2 mm², with a target optimization criterion of MLA ≥ 70% of the mean reference lumen area. Patients meeting both the intracoronary imaging criteria and angiographic safety criteria will proceed to DCB treatment. If these criteria are not achieved but angiographic safety criteria are satisfied and the patient remains clinically stable, further optimization may be considered. If angiographic safety criteria remain unmet after observation, bailout drug-eluting stent (DES) implantation will be performed.

Comparador activo: CAG-guided Drug-coated balloon strategy

In the CAG-guided group, DCB treatment will be guided by conventional coronary angiography, with DCB diameter and length determined by visual angiographic assessment.

For patients randomized to the CAG-guided group, the selection of lesion preparation devices, DCB sizing, and the need for bailout stenting will be determined by the operators based on coronary angiographic findings and clinical judgment. Patients meeting the predefined angiographic safety criteria after lesion preparation will proceed to DCB treatment. Bailout drug-eluting stent (DES) implantation will be performed if angiographic safety criteria are not met.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Target vessel failure
Periodo de tiempo: 12 months

Incidence of a composite of cardiac death, target-vessel myocardial infarction and clinically indicated target vessel revascularization

12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Device success
Periodo de tiempo: 0 day (during index PCI)
  • Successful delivery in time and inflation within 30-60 s of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use)
  • Successful delivery at the target lesion with final in-device residual stenosis ≤ 30% (DCB) or ≤ 20% (DES) by core laboratory QCA (preferred methodology) or visual assessment
  • No rescue procedure by stent
0 day (during index PCI)
Procedure success
Periodo de tiempo: 7 days

Device success Freedom from in-hospital TVF

7 days
Periprocedural complications
Periodo de tiempo: 48 hours

Incidence of a composite of cardiac death, periprocedural myocardial infarction, acute target lesion/vessel thrombosis, and acute target lesion/vessel occlusion

48 hours
Incidence of cardiac death
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Incidence of cardiac death

1, 12, 24, 36, and 60 months
Incidence of target-vessel myocardial infarction
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Incidence of target-vessel myocardial infarction

1, 12, 24, 36, and 60 months
Incidence of clinically indicated target vessel revascularization
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Incidence of clinically indicated target vessel revascularization

1, 12, 24, 36, and 60 months
Patient-oriented composite endpoint (PoCE)
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Incidence of a composite of all-cause mortality, any myocardial infarction, any stroke, and any revascularization

1, 12, 24, 36, and 60 months
all-cause mortality
Periodo de tiempo: 1, 12, 24, 36, and 60 months

all-cause mortality

1, 12, 24, 36, and 60 months
Any myocardial infarction
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Any myocardial infarction

1, 12, 24, 36, and 60 months
Any stroke
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Any stroke

1, 12, 24, 36, and 60 months
Any revascularization
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Any revascularization

1, 12, 24, 36, and 60 months
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding)
Periodo de tiempo: 1,12, 24, 36, and 60 months

Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding (Bleeding type 3 or 5 according to the Bleeding ARC))

1,12, 24, 36, and 60 months
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)
Periodo de tiempo: 1, 12, 24, 36, and 60 months

Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)

1, 12, 24, 36, and 60 months
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR
Periodo de tiempo: 1, 12, 24, 36 and 60 months

Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR

1, 12, 24, 36 and 60 months
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events
Periodo de tiempo: 1, 12, 24, 36 and 60 months

Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events

1, 12, 24, 36 and 60 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

31 de diciembre de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2031

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Deidentified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request and approval of a methodologically sound research proposal, subject to an appropriate data use agreement.

Marco de tiempo para compartir IPD

Beginning 36 months after publication of the primary study results and continuing for 5 years.

Criterios de acceso compartido de IPD

Deidentified individual participant data underlying the results reported in the primary publication will be available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where applicable, relevant institutional or ethics authorities. Proposals that substantially overlap with prespecified ongoing analyses may be deferred until completion of those analyses. Data will be provided for the purposes specified in the approved proposal, subject to an appropriate data use agreement and applicable privacy and data protection requirements.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir